John Hartley is Professor of Cancer Studies at UCL. He is also Director of the Cancer Research UK Drug-DNA Interactions Research Group and Co-Lead of the UCL Experimental Cancer Medicine Centre. Prior to joining UCL he was a Visiting Fellow at the National Cancer Institute, USA and an Alberta Heritage Research Fellow at the University of Alberta, Canada.
John has a B.Sc. in Biochemistry and a Ph.D. in Experimental Chemotherapy from the University of Manchester. He has 300 publications in the fields of molecular and clinical pharmacology, DNA damage and repair, drug design and development, and cancer therapeutics.
He was one of the founders of Spirogen Ltd, which was acquired by Astazeneca in 2013, and is currently Director of Preclinical Development. He is also an Advisor to ADC Therapeutics. He is a Fellow of both the Royal Societies of Biology and Chemistry and is an Honorary Member of the Royal College of Radiologists. He is also Chair of the Protocol Safety and Review Board of Cancer Research UK.